Pulmonary arterial hypertension (pah)
Drug research and approvals for pulmonary arterial hypertension (pah): what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 16, 2026, 102 studies of pulmonary arterial hypertension (pah) are recruiting on ClinicalTrials.gov, Health Canada has authorized 45 drug trials for it since 2013, FDA has 21 approved and 49 open orphan designations naming it, and the EU has 15 authorised medicines for it.
- Recruiting worldwide: 102
- Trials authorized in Canada: 45
- FDA orphan approvals: 21
- EU medicines: 15
Recruiting Now
Newest start dates first, of 102 recruiting on ClinicalTrials.gov ↗- Understanding the Effects of Pulmonary Arterial Hypertension on Lean Muscle Mass-SubstudyNCT07781709 · Not applicable · University of Pennsylvania · starts Nov 2, 2026
- The Effect of Additive On-Demand Sildenafil vs. Dextrose Candy on Maximum Exercise Capacity in Pulmonary Arterial…NCT07824674 · Phase 2 / Phase 3 · Silvia Ulrich · starts Oct 26, 2026
- Rehabilitation Program for People With Methamphetamine-Associated Cardiopulmonary ConditionsNCT07915882 · Not applicable · Michael Incze · starts Oct 13, 2026
- A Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) in India (MK-7962-037)NCT07600723 · Phase 4 · Merck Sharp & Dohme LLC · starts Oct 8, 2026
- Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Pulmonary Vascular Disease (PVD)NCT07777445 · Not applicable · Silvia Ulrich Somaini · starts Oct 1, 2026
- Exercise Performance on Ambient Air vs. Low-Flow Liquid Oxygen Therapy in Chronic Lung DiseasesNCT07777367 · Not applicable · Silvia Ulrich Somaini · starts Oct 1, 2026
- PAH-SDB: Sleep-Disordered Breathing and Outcomes in Pulmonary Arterial HypertensionNCT07852403 · Not reported · Chinese Pulmonary Vascular Disease Research Group · starts Oct 1, 2026
- Clinical Trial of NS-863 in Participants With Pulmonary Arterial Hypertension (PAH)NCT07441200 · Phase 2 · NS Pharma, Inc. · starts Sep 29, 2026
- Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74)…NCT07613099 · Phase 3 · National Heart, Lung, and Blood Institute (NHLBI) · starts Sep 18, 2026
- A Study of Sotatercept (MK-7962) in Japanese Children With Pulmonary Arterial Hypertension (PAH) (MK-7962-032)NCT07646860 · Phase 2 · Merck Sharp & Dohme LLC · starts Sep 17, 2026
Trials Authorized in Canada
The 10 newest of 45; search them all in Canada trials| May 20, 2026 | A phase 3, randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of once daily treprostinil…TREPROSTINIL (INS1009) | Insmed | Pending |
| Mar 26, 2026 | An adaptive, 2-part randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of ikt-001 in pulmonary arterial hypertensionIKT-001 | INHIBIKASE THERAPEUTICS, INC. | Ongoing |
| Oct 24, 2025 | A phase 2b, randomized, double-blind, placebo-controlled trial of ikt-001 in pulmonary arterial hypertensionIKT-001 | INHIBIKASE THERAPEUTICS, INC. | Closed |
| Sep 23, 2025 | A phase 2a, open-label, single arm multicenter exploratory study to evaluate the safety, tolerability, and efficacy of oral doses of roc-101 in patients with…ROC-101 | ALLROCK BIO, INC. | Ongoing |
| Sep 18, 2025 | An open-label long-term follow-up study to evaluate the effects of sotatercept when added to background pulmonary arterial hypertension (pah) therapy for the…WINREVAIR | Merck & Co. (MSD) | Ongoing |
| Aug 7, 2025 | A phase 2, open-label extension study to investigate the safety and efficacy of pf-07868489 administered to adult participants with pulmonary arterial…PF-07868489 | Pfizer | Closed |
| Jul 29, 2025 | A phase lb, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study assessing the safety, pharmacokinetics, pharmacodynamies, and…HS235 | 35PHARMA INC. | Pending |
| Apr 29, 2025 | An open-label extension study to evaluate safety and tolerability of sotatercept (mk-7962) administered using a weight-banded approach in participants with…SOTATERCEPT (MK-7962) | Merck & Co. (MSD) | Pending |
| Nov 28, 2024 | A phase 1 / 2, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single…PF-07868489 | Pfizer | Closed |
| Sep 17, 2024 | A phase 2, multicenter, single-blinded, randomized study to evaluate the pharmacokinetics and safety of sotatercept (mk-7962) administered using either a…MK-7962 (SOTATERCEPT) | Merck & Co. (MSD) | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first; 15 of 70| May 23, 2026 | Uptravitreatment of PAH (WHO Group I) in pediatric patients aged two years and older. Uptravi reduces NT-proBNP and is expected to delay disease… | Actelion Pharmaceuticals Ltd | Approved |
| Oct 24, 2025 | Winrevairtreatment of adults with pulmonary arterial hypertension (PAH, Group 1 pulmonary hypertension) to improve exercise capacity and World… | Merck Sharp & Dohme LLC | Approved |
| Mar 26, 2024 | Winrevairtreatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group 1) to increase exercise capacity,… | Merck Sharp & Dohme LLC | Approved |
| Mar 22, 2024 | Opsynvichronic treatment of adults with pulmonary arterial hypertension (PAH, WHO Group I and WHO Functional Class (FC) II-III) | Actelion Pharmaceuticals US, Inc. | Approved |
| Mar 3, 2023 | Revatiotreatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients (1 to 17 years old) to improve exercise ability and,… | Viatris Specialty LLC | Approved |
| Jan 31, 2023 | Revatiotreatment of pulmonary arterial hypertension (PAH) (WHO Group I) in pediatric patients 1 to 17 years old to improve exercise ability and,… | Viatris Specialty LLC | Approved |
| May 23, 2022 | Tyvaso DPITreatment of pulmonary arterial hypertension (PAH; WHO Group 1) to improve exercise ability | United Therapeutics Corporation | Approved |
| Jul 29, 2021 | UptraviTreatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for PAH | Actelion Pharmaceuticals Ltd | Approved |
| Oct 18, 2019 | Remodulin;OrenitramOrenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to delay disease progression and to improve… | United Therapeutics Corp. | Approved |
| Sep 5, 2017 | TracleerTreatment of pulmonary arterial hypertension (PAH) (WHO Group 1) in pediatric patients aged 3 years and older with idiopathic or congenital… | Actelion Pharmaceuticals Ltd | Approved |
| Dec 21, 2015 | UptraviFor treatment of pulmonary arterial hypertension (PAH, WHO Group I) to delay disease progression and reduce the risk of hospitalization for… | Actelion Pharmaceuticals Ltd | Approved |
| Dec 20, 2013 | Remodulin;OrenitramOrenitram is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. | United Therapeutics Corp. | Approved |
| Oct 18, 2013 | OpsumitTreatment of pulmonary arterial hypertension (PAH, WHO Group 1) to delay disease progression. Disease progression included: death,… | Actelion Pharmaceuticals Ltd | Approved |
| Oct 8, 2013 | AdempasTreatment of adults with pulmonary arterial hypertension (PAH) WHO Group 1, to improve exercise capacity, WHO functional class and to delay… | Bayer HealthCare Pharmaceuticals, Inc. | Approved |
| Jul 30, 2009 | TyvasoTreatment of pulmonary arterial hypertension (WHO Group I) in patients with NYHA Class III symptoms, to increase walk distance | United Therapeutics Corporation | Approved |
Medicines Authorised in the EU
Newest firstCondition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA